Home > Insider Trading > Filing (0001209191-11-013030)

Filing Details

Accession Number:: 0001209191-11-013030
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2011-02-25 18:40:53
Reporting Period:: 2011-02-23

Filing Date:: 2011-02-25
Accepted Time:: 2011-02-25 18:40:53
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1100962	Endo Pharmaceuticals Holdings Inc	ENDP	Pharmaceutical Preparations (2834)	134022871

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1328288	P. Ivan Gergel	C/O Endo Pharmaceuticals 100 Endo Boulevard Chadds Ford PA 19317	Evp, Research & Development	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock, Par Value, $.01 Pershare	Acquisiton	2011-02-24	15,742	$20.61	15,742	No	4	M	Direct
Common Stock, Par Value, $.01 Pershare	Disposition	2011-02-24	15,742	$33.59	0	No	4	S	Direct
2010 Stock Incentive Plan Restricted Stock Units (Rsu)	Acquisiton	2011-02-23	13,316	$0.00	13,316	No	4	M	Direct
2010 Stock Incentive Plan Performance Shares	Acquisiton	2011-02-23	13,316	$0.00	13,316	No	4	M	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	2007 Stock Incentive Plan Options	Disposition	2011-02-24	15,742	$0.00	15,742	$20.61
Common Stock	2010 Stock Incentive Plan Stock Options	Acquisiton	2011-02-23	41,549	$0.00	41,549	$33.98

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
47,226		2020-02-19	No	4	M	Direct
41,549		2021-02-23	No	4	A	Direct

Footnotes

On December 3, 2010, Dr. Gergel placed 58,845 of the shares underlying his stock options into a 10b5-1 pre-set selling program until December 31, 2011 (the "Gergel Pre-Set Selling Program"). The options exercised and the shares sold here were sold pursuant to the Gergel Pre-Set Selling Program, which leaves 43,103 shares (underlying options) in the Gergel Pre-Set Selling Program.
This represents the average price at which Dr. Gergel's common shares were sold on on February 24, 2011.
Upon each vesting date, each vested restricted stock unit automatically converts into one (1) share of Endo Pharmaceuticals Holdings Inc. common stock. These restricted stock units (RSUs) are generally exercisable 25% per year on each of February 23, 2012, February 23, 2013, February 23, 2014 and February 23, 2015. Upon vesting, we consider the underlying RSUs to be expired.
These securities were granted to Dr. Gergel in consideration of his services as the Executive Vice President, Research & Development of Endo Pharmaceuticals Holdings Inc.
The performance shares vest upon the Company achieving certain financial targets.
Represents target quantity of shares issuable. The exact number of shares issuable will be determined on achievement of certain company performance targets over a cumulative 3-year period, as determined by the Compensation Committee of the Board of Directors of Endo Pharmaceuticals Holdings Inc. The executive can earn between 0% and 200% of the target shares.
Dr. Gergel's stock options that were granted under the 2007 Stock Incentive Plan on February 19, 2010, are generally exercisable 25% per year on each of February 19, 2011, February 19, 2012, February 19, 2013 and February 19, 2014. The 15,742 stock options that were exercised now are those that became exercisable on February 19, 2011.
Representing the right to buy shares of common stock, par value $0.01 per share, of Endo Pharmaceuticals Holdings Inc.
These stock options are generally exercisable 25% per year on each of February 23, 2012, February 23, 2013, February 23, 2014 and February 23, 2015.